Literature DB >> 19958089

Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.

Navin Pinto1, Susan M Ludeman, M Eileen Dolan.   

Abstract

Cyclophosphamide is a cornerstone in the treatment of many pediatric and adult malignancies, as well as in the treatment of refractory autoimmune conditions. Genetic factors are thought to play a role in the interindividual variation in both response and toxicities associated with cyclophosphamide-based therapies. This drug focus reviews the most compelling studies conducted on the pharmacogenetics of cyclophosphamide-based therapies. Broader pharmacogenomic studies are needed and may reveal additional factors important in susceptibility to toxicity and/or response to therapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19958089      PMCID： PMC2820268          DOI： 10.2217/pgs.09.134

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


  60 in total

1.  Increased transcriptional activity of the CYP3A4*1B promoter variant.

Authors:  B Amirimani; B Ning; A C Deitz; B L Weber; F F Kadlubar; T R Rebbeck
Journal:  Environ Mol Mutagen       Date:  2003       Impact factor: 3.216

Review 2.  Molecular epidemiology: on the path to prevention?

Authors:  F P Perera
Journal:  J Natl Cancer Inst       Date:  2000-04-19       Impact factor: 13.506

3.  Role of O6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity.

Authors:  Y Cai; M H Wu; S M Ludeman; D J Grdina; M E Dolan
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

4.  Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study.

Authors:  M Stanulla; M Schrappe; A M Brechlin; M Zimmermann; K Welte
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

5.  Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma.

Authors:  Stefan Hohaus; Annalisa Di Ruscio; Annalaura Di Febo; Giuseppina Massini; Francesco D'Alo'; Francesco Guidi; Giovanna Mansueto; Maria Teresa Voso; Giuseppe Leone
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

6.  Differential protection against benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide-induced DNA damage in HepG2 cells stably transfected with allelic variants of pi class human glutathione S-transferase.

Authors:  X Hu; C Herzog; P Zimniak; S V Singh
Journal:  Cancer Res       Date:  1999-05-15       Impact factor: 12.701

7.  Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma.

Authors:  Gong Yang; Xiao-Ou Shu; Zhi-Xian Ruan; Qiu-Yin Cai; Fan Jin; Yu-Tang Gao; Wei Zheng
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

8.  Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism.

Authors:  S Pemble; K R Schroeder; S R Spencer; D J Meyer; E Hallier; H M Bolt; B Ketterer; J B Taylor
Journal:  Biochem J       Date:  1994-05-15       Impact factor: 3.857

9.  Evaluation of aldehyde dehydrogenase 1 promoter polymorphisms identified in human populations.

Authors:  John P Spence; Tiebing Liang; C J Peter Eriksson; Robert E Taylor; Tamara L Wall; Cindy L Ehlers; Lucinda G Carr
Journal:  Alcohol Clin Exp Res       Date:  2003-09       Impact factor: 3.455

10.  Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione.

Authors:  H A Dirven; B van Ommen; P J van Bladeren
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701
View more
  28 in total

1.  Pharmacokinetics of cyclophosphamide after oral and intravenous administration to dogs with lymphoma.

Authors:  E Warry; R J Hansen; D L Gustafson; S E Lana
Journal:  J Vet Intern Med       Date:  2011-05-12       Impact factor: 3.333

2.  Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study.

Authors:  Daniel M Green; Wei Liu; William H Kutteh; Raymond W Ke; Kyla C Shelton; Charles A Sklar; Wassim Chemaitilly; Ching-Hon Pui; James L Klosky; Sheri L Spunt; Monika L Metzger; DeoKumar Srivastava; Kirsten K Ness; Leslie L Robison; Melissa M Hudson
Journal:  Lancet Oncol       Date:  2014-09-16       Impact factor: 41.316

3.  Cyclophosphamide and fludarabine monophosphate dose optimization for the non-myeloablative condition in non-human primates to induce transient mixed chimerism via bone marrow transplantation.

Authors:  Yeongbeen Kwon; Kyo Won Lee; Hyojun Park; Jin Kyung Son; JongHyun Lee; Chan Woo Cho; Ghee Young Kwon; Jae Berm Park; Sung Joo Kim
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

4.  Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo.

Authors:  Brianne S Raccor; Adam J Claessens; Jean C Dinh; Julie R Park; Douglas S Hawkins; Sushma S Thomas; Karen W Makar; Jeannine S McCune; Rheem A Totah
Journal:  Drug Metab Dispos       Date:  2011-10-05       Impact factor: 3.922

5.  Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients.

Authors:  Md Siddiqul Islam; Mohammad Safiqul Islam; Salma Parvin; Maizbah Uddin Ahmed; Muhammad Shahdaat Bin Sayeed; Mir Muhammad Nasir Uddin; Syed Md Akram Hussain; Abul Hasnat
Journal:  Tumour Biol       Date:  2015-02-13

6.  GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis.

Authors:  Elizabeth Ann Coleman; Jeannette Y Lee; Stephen W Erickson; Julia A Goodwin; Naveen Sanathkumar; Vinay R Raj; Daohong Zhou; Kent D McKelvey; Senu Apewokin; Owen Stephens; Carol A Enderlin; Annette Juul Vangsted; Patty J Reed; Elias J Anaissie
Journal:  Support Care Cancer       Date:  2014-09-14       Impact factor: 3.603

Review 7.  Pharmacogenomics of breast cancer therapy: an update.

Authors:  Kelly Westbrook; Vered Stearns
Journal:  Pharmacol Ther       Date:  2013-03-13       Impact factor: 12.310

Review 8.  Cyclophosphamide-induced severe acute hepatitis in a rheumatic disease: case-based review.

Authors:  Döndü Üsküdar Cansu; Erkin Öztaş; Evrim Yilmaz; Cengiz Korkmaz
Journal:  Rheumatol Int       Date:  2018-10-30       Impact factor: 2.631

9.  Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array.

Authors:  Sourav Kalra; Raman Preet Kaur; Abhilash Ludhiadch; Gowhar Shafi; Rajesh Vashista; Raj Kumar; Anjana Munshi
Journal:  Eur J Clin Pharmacol       Date:  2018-06-24       Impact factor: 2.953

10.  Ovarian xenobiotic biotransformation enzymes are altered during phosphoramide mustard-induced ovotoxicity.

Authors:  Jill A Madden; Aileen F Keating
Journal:  Toxicol Sci       Date:  2014-07-28       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.